Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Auckland, New Zealand
About this trial
The goal of this single-arm intervention trial is to determine the feasibility of implementing endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel for intraductal papillary mucinous neoplasms (IPMN) in two New Zealand tertiary interventional endoscopy centres.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Radiological diagnosis of branch duct IPMN.
Cyst size of 3cm or worrying growth on serial imaging.
Suitable to undergo endoscopy under deep sedation or general anaesthesia.
Disqualifiers
Presence of known or suspected pancreatic cancer or pathologic lymphadenopathy.
Main pancreatic duct dilation of >10 mm
Cytology with high grade dysplasia or "suspicious for malignancy"
Common bile duct obstruction causing jaundice
Trial design
Treatments tested in this trial
- Endoscopic ultrasound-guided pancreatic cyst chemoablation (EUS-PCA) using gemcitabine and paclitaxel
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Auckland, New Zealand
Lead sponsor
Gut Cancer Foundation, New Zealand
Collaborator
North Shore Hospital, New Zealand
Collaborator
Waikato Hospital
Collaborator
Source ClinicalTrials.gov